149 related articles for article (PubMed ID: 34237262)
1. The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi.
Glynn JR; Dube A; Fielding K; Crampin AC; ; Kanjala C; Fine PEM
Lancet Infect Dis; 2021 Nov; 21(11):1590-1597. PubMed ID: 34237262
[TBL] [Abstract][Full Text] [Related]
2. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.
Lancet; 1996 Jul; 348(9019):17-24. PubMed ID: 8691924
[TBL] [Abstract][Full Text] [Related]
3. The Karonga Prevention Trial: a leprosy and tuberculosis vaccine trial in northern Malaŵi. I. Methods of the vaccination phase.
Pönnighaus JM; Fine PE; Bliss L; Gruer PJ; Kapira-Mwamondwe B; Msosa E; Rees RJ; Clayton D; Pike MC; Sterne JA
Lepr Rev; 1993 Dec; 64(4):338-56. PubMed ID: 8127221
[TBL] [Abstract][Full Text] [Related]
4. BCG re-vaccination in Malawi: 30-year follow-up of a large, randomised, double-blind, placebo-controlled trial.
Glynn JR; Fielding K; Mzembe T; Sichali L; Banda L; McLean E; Kanjala C; Crampin AC; Ponnighaus JM; Warndorff DK; Fine PEM;
Lancet Glob Health; 2021 Oct; 9(10):e1451-e1459. PubMed ID: 34534489
[TBL] [Abstract][Full Text] [Related]
5. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
Tameris M; Mearns H; Penn-Nicholson A; Gregg Y; Bilek N; Mabwe S; Geldenhuys H; Shenje J; Luabeya AKK; Murillo I; Doce J; Aguilo N; Marinova D; Puentes E; Rodríguez E; Gonzalo-Asensio J; Fritzell B; Thole J; Martin C; Scriba TJ; Hatherill M;
Lancet Respir Med; 2019 Sep; 7(9):757-770. PubMed ID: 31416768
[TBL] [Abstract][Full Text] [Related]
6. Leprosy in Malawi. 2. Background, design and prospects of the Karonga Prevention Trial, a leprosy vaccine trial in northern Malawi.
Fine PE; Ponnighaus JM
Trans R Soc Trop Med Hyg; 1988; 82(6):810-7. PubMed ID: 3076995
[TBL] [Abstract][Full Text] [Related]
7. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity.
Fine PE; Sterne JA; Pönnighaus JM; Rees RJ
Lancet; 1994 Nov; 344(8932):1245-9. PubMed ID: 7967984
[TBL] [Abstract][Full Text] [Related]
8. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial.
Rodrigues LC; Pereira SM; Cunha SS; Genser B; Ichihara MY; de Brito SC; Hijjar MA; Dourado I; Cruz AA; Sant'Anna C; Bierrenbach AL; Barreto ML
Lancet; 2005 Oct; 366(9493):1290-5. PubMed ID: 16214599
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.
Pönnighaus JM; Fine PE; Sterne JA; Wilson RJ; Msosa E; Gruer PJ; Jenkins PA; Lucas SB; Liomba NG; Bliss L
Lancet; 1992 Mar; 339(8794):636-9. PubMed ID: 1347338
[TBL] [Abstract][Full Text] [Related]
10. Incidence rates of leprosy in Karonga District, northern Malawi: patterns by age, sex, BCG status and classification.
Pönnighaus JM; Fine PE; Sterne JA; Bliss L; Wilson RJ; Malema SS; Kileta S
Int J Lepr Other Mycobact Dis; 1994 Mar; 62(1):10-23. PubMed ID: 8189075
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
Tameris MD; Hatherill M; Landry BS; Scriba TJ; Snowden MA; Lockhart S; Shea JE; McClain JB; Hussey GD; Hanekom WA; Mahomed H; McShane H;
Lancet; 2013 Mar; 381(9871):1021-8. PubMed ID: 23391465
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Junqueira-Kipnis AP; Dos Anjos LRB; Barbosa LCS; da Costa AC; Borges KCM; Cardoso ADRO; Ribeiro KM; Rosa SBA; Souza CC; das Neves RC; Saraiva G; da Silva SM; Silveira EA; Rabahi MF; Conte MB; Kipnis A
Trials; 2020 Oct; 21(1):881. PubMed ID: 33106170
[TBL] [Abstract][Full Text] [Related]
14. Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau.
Roth AE; Benn CS; Ravn H; Rodrigues A; Lisse IM; Yazdanbakhsh M; Whittle H; Aaby P
BMJ; 2010 Mar; 340():c671. PubMed ID: 20231251
[TBL] [Abstract][Full Text] [Related]
15. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.
Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS
Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115
[TBL] [Abstract][Full Text] [Related]
16. Protective efficacy of BCG against leprosy in Northern Malawi.
Fine PE; Ponnighaus JM; Maine N; Clarkson JA; Bliss L
Lancet; 1986 Aug; 2(8505):499-502. PubMed ID: 2875247
[TBL] [Abstract][Full Text] [Related]
17. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results.
Convit J; Sampson C; Zúñiga M; Smith PG; Plata J; Silva J; Molina J; Pinardi ME; Bloom BR; Salgado A
Lancet; 1992 Feb; 339(8791):446-50. PubMed ID: 1346818
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial.
Pereira SM; Barreto ML; Pilger D; Cruz AA; Sant'Anna C; Hijjar MA; Ichihara MY; Santos AC; Genser B; Rodrigues LC
Lancet Infect Dis; 2012 Apr; 12(4):300-6. PubMed ID: 22071248
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
